XML 18 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8
RESTRUCTURING AND OTHER SPECIAL CHARGES
6 Months Ended
Jun. 30, 2013
Restructuring and Related Activities [Abstract]  
Restructuring and Other Special Charges
RESTRUCTURING AND OTHER SPECIAL CHARGES

During the first six months of 2013, the Company recorded net restructuring charges of $14.1. The charges were comprised of $10.1 in severance and other personnel costs along with $6.3 in costs associated with facility closures and general integration initiatives. These charges were offset by the reversal of previously established reserves of $0.6 in unused severance and $1.7 in unused facility-related costs.

During the first six months of 2012, the Company recorded a net credit of $0.2 in restructuring and other special charges. The Company reversed previously established reserves of $4.8 in unused severance and $2.9 in unused facility related costs. This net credit also includes charges of $6.2 related to severance and other personnel costs, and $1.3 primarily related to facility-related costs primarily related to ongoing integration activities for Clearstone Central Laboratories, Orchid Cellmark Inc. ("Orchid") and the Integrated Genetics Division (formerly Genzyme Genetics*) and costs associated with the previously announced termination of an executive vice president.

As part of the Clearstone integration, the Company also recorded a $6.9 loss on the disposal of one its European subsidiaries in Other, net under Other income (expenses) during the three months ended June 30, 2012.

* Genzyme Genetics and its logo are trademarks of Genzyme Corporation and used by Esoterix Genetic Laboratories, LLC, a wholly-owned subsidiary of LabCorp, under license. Esoterix Genetic Laboratories and LabCorp are operated independently from Genzyme Corporation.